PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 9101783

[Thoracic neuroblastoma].

B Schmidt·M E Höllwarth·J Schalamon·C Urban
View original source ↗Export metadata ↓

Abstract

Between 1984 and 1994 operations for thoracic neuroblastomas were performed in ten patients (six boys, four girls). The median age was 17 months, the follow-up ranges between 6 months and 11 years; one patient died 3 years postoperatively. Complete excision of the tumour was the only therapy in four patients presenting with stage I (n = 2) and II a (n = 2) disease. Following resection, chemotherapy was carried out in four patients with stage II b (n = 2) and III (n = 2). Chemotherapy was the primary procedure in two patients with stage IV; resection of the tumour and postoperative chemotherapy followed. Thoracic neuroblastomas have a favorable outcome. The basic biology seems to differ from that of other sites and may not warrant such aggressive surgical therapy. Complete excision is recommended, if possible, but is not imperative.

Explore related subjects

Chemotherapy, AdjuvantChildChild, PreschoolCombined Modality TherapyFemaleHumansInfantMagnetic Resonance ImagingMaleNeoplasm StagingNeuroblastomaPrognosisSurvival RateThoracic NeoplasmsEnglish AbstractJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

B Schmidt, M E Höllwarth, J Schalamon, C Urban. 1996. [Thoracic neuroblastoma].. https://pubmed.ncbi.nlm.nih.gov/9101783/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Safe fertility-preserving management in gynecological malignancies.

OBJECTIVE: To provide a review in the available literature about the safe fertility-preserving management in gynecological malignancies, focusing on the selection criteria of the patients, treatment options and follow-up. DESIGN: Literature survey. RESULTS: The incidence of cancer in women who still want to get pregnant is increasing significantly. An early detection in gynecological malignancies allows less aggressive approaches to cure such disorders. A more conservative management, which preserves fertility, is considered safe and an option for those who have not completed their child-bearing. CONCLUSIONS: Selected patients with cervical, endometrial and ovarian cancer may be candidates to a safe fertility-preserving management. A careful stage and follow-up of the patients is essential to achieve success with this practice.

Chemotherapy, Adjuvant↗
PubMed2007

Defining optimal therapy for muscle invasive bladder cancer.

PURPOSE: We defined an optimal curative strategy for muscle invasive bladder cancer and to determine how best to deliver curative therapy. MATERIALS AND METHODS: We reviewed published reports from 1985 to 2006 dealing with the treatment of muscle invasive (stage T2-T4a) bladder cancer. We analyzed all cohort, phase II and randomized phase III studies providing level 1 to 3 evidence impacting survival. RESULTS: Cisplatin based chemotherapy combined with high quality radical cystectomy and complete pelvic lymph node dissection improves survival over that of cystectomy alone. Surgery quality is an important predictor of survival even in patients receiving chemotherapy. Neoadjuvant chemotherapy is favored over adjuvant chemotherapy because it is better tolerated and more patients are able to receive effective therapy before rather than after surgery. CONCLUSIONS: Neoadjuvant chemotherapy followed by radical cystectomy and complete pelvic lymph node dissection is the optimal curative strategy in most patients presenting with muscle invasive bladder cancer.

Chemotherapy, Adjuvant↗